Head to Head Analysis: Invivo Therapeutics (NASDAQ:NVIV) and Vapotherm (NASDAQ:VAPO) – Slater Sentinel

Invivo Therapeutics (NASDAQ:NVIV) and Vapotherm (NYSE:VAPO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations and institutional ownership.

Profitability

This table compares Invivo Therapeutics and Vapotherms net margins, return on equity and return on assets.

This table compares Invivo Therapeutics and Vapotherms top-line revenue, earnings per share (EPS) and valuation.

Invivo Therapeutics has higher earnings, but lower revenue than Vapotherm. Vapotherm is trading at a lower price-to-earnings ratio than Invivo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

7.0% of Invivo Therapeutics shares are owned by institutional investors. Comparatively, 60.0% of Vapotherm shares are owned by institutional investors. 0.3% of Invivo Therapeutics shares are owned by company insiders. Comparatively, 34.4% of Vapotherm shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Invivo Therapeutics and Vapotherm, as reported by MarketBeat.

Vapotherm has a consensus target price of $26.50, indicating a potential upside of 139.60%. Given Vapotherms higher possible upside, analysts clearly believe Vapotherm is more favorable than Invivo Therapeutics.

Summary

Vapotherm beats Invivo Therapeutics on 6 of the 11 factors compared between the two stocks.

Invivo Therapeutics Company Profile

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. has research collaboration with the Q Therapeutics, Inc. for the evaluation of the combination of PLGA-PLL based Neuro-Spinal Scaffold with adult neural progenitor cells, including those from induced pluripotent stem cells. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.

Vapotherm Company Profile

Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit and Q50 compressor; and disposable products comprising single-use disposables and nasal interfaces. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.

Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Go here to read the rest:
Head to Head Analysis: Invivo Therapeutics (NASDAQ:NVIV) and Vapotherm (NASDAQ:VAPO) - Slater Sentinel